Citations

Showing 10 of 108152 citations.

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update
Moy, Beverly, Rumble, R. Bryan, Come, Steven E. , Davidson, Nancy E., Leo, Angelo Di , Gralow, Julie R. , Hortobágyi, Gabriel N. , Yee, Douglas , Smith, Ian E., Chávez‐MacGregor, Mariana , Nanda, Rita , McArthur, Heather L. , Reeder‐Hayes, Katherine E. , Ruddy, Kathryn J. , Unger, Paul S. , Vinayak, Shaveta, Irvin, William J., Armaghani, Avan, Danso, Michael A., Dickson, Natalie R. , Turner, Sophie S., Perkins, Cheryl L., Di Leo, Angelo , Spring, Laura , Reeder-Hayes, Katherine , Ruddy, Kathryn J , Unger, Paul S , Dickson, Natalie , Carey, Lisa A , Come, Steven , Hortobagyi, Gabriel N , Gralow, Julie R , Yee, Douglas , Chavez-MacGregor, Mariana , Moy, Beverly, Rumble, R. Bryan, Davidson, Nancy E., Smith, Ian E., Nanda, Rita , McArthur, Heather , Vinayak, Shaveta, Irvin, William J., Armaghani, Avan, Danso, Michael A., Turner, Sophie S., Perkins, Cheryl L.

Mayo Clinic

Journal of Clinical Oncology | July 29, 2021 | Volume: 39 | Issue: 35 | Pages: 3938-3958

10.1200/jco.21.01374 | PMID 34324366 Get It

PURPOSE This guideline updates recommendations of the ASCO guideline on chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2–negative metastatic breast cancer (MBC) that is either endocrine-pretreated or hormone receptor (HR)–negative. METHODS An Expert Panel conducted a targeted systematic literature review guided by a signals approach to identify new, potentially practice-changing data that might translate into revised guideline recommendations. RESULTS The Expert Panel reviewed abstracts from the literature review and retained 14 articles. RECOMMENDATIONS Patients with triple-negative, programmed cell death ligand-1–positive MBC may be offered the addition of immune checkpoint inhibitor to chemotherapy as first-line therapy. Patients with triple-negative, programmed cell death ligand-1–negative MBC should be offered single-agent chemotherapy rather than combination chemotherapy as first-line treatment, although combination regimens may be offered for life-threatening disease. Patients with triple-negative MBC who have received at least two prior therapies for MBC should be offered treatment with sacituzumab govitecan. Patients with triple-negative MBC with germline BRCA mutations previously treated with chemotherapy may be offered a poly (ADP-ribose) polymerase inhibitor rather than chemotherapy. Patients with HR-positive human epidermal growth factor receptor 2–negative MBC for whom chemotherapy is being considered should be offered single–agent chemotherapy rather than combination chemotherapy, although combination regimens may be offered for highly symptomatic or life-threatening disease. Patients with HR-positive MBC with disease progression on an endocrine agent may be offered treatment with either endocrine therapy with or without targeted therapy or single-agent chemotherapy. Patients with HR-positive MBC with germline BRCA mutations no longer benefiting from endocrine therapy may be offered a poly (ADP-ribose) polymerase inhibitor rather than chemotherapy. No recommendation regarding when a patient's care should be transitioned to hospice or best supportive care alone is possible. Additional information is available at www.asco.org/breast-cancer-guidelines .
Tongue muscle contractile, fatigue, and fiber type properties in rats
Fogarty, Matthew J. , Sieck, Gary C. , Sieck, Gary , Fogarty, Matthew J

Mayo Clinic

Journal of Applied Physiology | July 29, 2021 | Volume: 131 | Issue: 3 | Pages: 1043-1055

10.1152/japplphysiol.00329.2021 | PMID 34323593 Get It

For the individual tongue muscles, relatively little quantification of uniaxial force, fatigue, and fiber type-specific properties has been documented. Here, we assessed uniaxial-specific force generation, fatigability, and muscle fiber type-specific properties in the superior and inferior longitudinal muscles, the transversalis, and the genioglossus in Fischer 344 rats. The longitudinal muscles produced the greatest isometric tetanic-specific forces. The genioglossus was more fatigue resistant and comprised higher proportions of I and IIa fibers.
The Second Annual Symposium of the Midwest Aging Consortium: The Future of Aging Research in the Midwestern United States
Green, Cara L. , Englund, Davis A. , Das, Srijit , Herrerias, Mariana M, Yousefzadeh, Matthew J. , Grant, Rogan A. , Clark, Josef, Pak, Heidi H. , Liu, Peiduo , Prahlad, Veena , Lamming, Dudley W. , Chusyd, Daniella E. , Lamming, Dudley W , Herrerias, Mariana M, Clark, Josef P. , Bai, Hua , Englund, Davis A.

Mayo Clinic

The Journals of Gerontology: Series A | July 29, 2021 | Volume: 76 | Issue: 12 | Pages: 2156-2161

10.1093/gerona/glab210 | PMID 34323268 Get It

Abstract While the average human life span continues to increase, there is little evidence that this is leading to a contemporaneous increase in “healthy years” experienced by our aging population. Consequently, many scientists focus their research on understanding the process of aging and trialing interventions that can promote healthspan. The 2021 Midwest Aging Consortium consensus statement is to develop and further the understanding of aging and age-related disease using the wealth of expertise across universities in the Midwestern United States. This report summarizes the cutting-edge research covered in a virtual symposium held by a consortium of researchers in the Midwestern United States, spanning topics such as senescence biomarkers, serotonin-induced DNA protection, immune system development, multisystem impacts of aging, neural decline following severe infection, the unique transcriptional impact of calorie restriction of different fat depots, the pivotal role of fasting in calorie restriction, the impact of peroxisome dysfunction, and the influence of early life trauma on health. The symposium speakers presented data from studies conducted in a variety of common laboratory animals as well as less-common species, including Caenorhabditis elegans, Drosophila, mice, rhesus macaques, elephants, and humans. The consensus of the symposium speakers is that this consortium highlights the strength of aging research in the Midwestern United States as well as the benefits of a collaborative and diverse approach to geroscience.
The Emerging Role of Circulating Tumor DNA in the Management of Breast Cancer
Shoukry, Mira , Broccard, Sacha P. , Kaplan, Jamie L. , Gabriel, Emmanuel , Broccard, Sacha , Kaplan, Jamie, Gabriel, Emmanuel M

Mayo Clinic

Cancers | July 29, 2021 | Volume: 13 | Issue: 15 | Pages: 3813

10.3390/cancers13153813 | PMID 34359713 Get It

With the incidence of breast cancer steadily rising, it is important to explore novel technologies that can allow for earlier detection of disease as well more a personalized and effective treatment approach. The concept of “liquid biopsies” and the data they provide have been increasingly studied in the recent decades. More specifically, circulating tumor DNA (ctDNA) has emerged as a potential biomarker for various cancers, including breast cancer. While methods such as mammography and tissue biopsies are the current standards for the detection and surveillance of breast cancer, ctDNA analysis has shown some promise. This review discusses the versatility of ctDNA by exploring its multiple emerging uses for the management of breast cancer. Its efficacy is also compared to current biomarkers and technologies.
Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma
Pant, Kishor , Peixoto, Estanislao , Richard, Seth , Biswas, Aalekhya , O’Sullivan, M. Gerard , Giama, Nasra H., Ha, Yeonjung , Yin, Jun , Carotenuto, Pietro , Salati, Massimiliano, Ren, Yanan , Yang, Rendong , Roberts, Lewis R. , Gradilone, Sergio A. , O’Sullivan, M. Gerard , Giama, Nasra, Gradilone, Sergio A , Roberts, Lewis R , O'Sullivan, M Gerard , Salati, Massimiliano , Franco, Brunella

Mayo Clinic

Hepatology | July 29, 2021 | Volume: 74 | Issue: 6 | Pages: 3235-3248

10.1002/hep.32080 | PMID 34322899 Get It

Background and Aims Sirtuin 1 (SIRT1) is a complex NAD+‐dependent protein deacetylase known to act as a tumor promoter or suppressor in different cancers. Here, we describe a mechanism of SIRT1‐induced destabilization of primary cilia in cholangiocarcinoma (CCA). Approach and Results A significant overexpression of SIRT1 was detected in human CCA specimens and CCA cells including HuCCT1, KMCH, and WITT1 as compared with normal cholangiocytes (H69 and NHC). Small interfering RNA (siRNA)‐mediated knockdown of SIRT1 in HuCCT1 cells induced cilia formation, whereas overexpression of SIRT1 in normal cholangiocytes suppressed ciliary expression. Activity of SIRT1 was regulated by presence of NAD+ in CCA cells. Inhibition of NAD ‐producing enzyme nicotinamide phosphoribosyl transferase increased ciliary length and frequency in CCA cells and in SIRT1‐overexpressed H69 cells. Furthermore, we also noted that SIRT1 induces the proteasomal mediated degradation of ciliary proteins, including α‐tubulin, ARL13B, and KIF3A. Moreover, overexpression of SIRT1 in H69 and NHC cells significantly induced cell proliferation and, conversely, SIRT1 inhibition in HuCCT1 and KMCH cells using siRNA or sirtinol reduced cell proliferation. In an orthotopic transplantation rat CCA model, the SIRT1 inhibitor sirtinol reduced tumor size and tumorigenic proteins (glioma‐associated oncogene 1, phosphorylated extracellular signal‐regulated kinase, and IL‐6) expression. Conclusions In conclusion, these results reveal the tumorigenic role of SIRT1 through modulation of primary cilia formation and provide the rationale for developing therapeutic approaches for CCA using SIRT1 as a target.
The extravascular implantable cardioverter‐defibrillator: The pivotal study plan
Crozier, Ian , O’Donnell, David , Boersma, Lucas V.A. , Murgatroyd, Francis , Manlucu, Jaimie , Knight, Bradley P. , Birgersdotter‐Green, Ulrika , Leclercq, Christophe , Thompson, Amy , Sawchuk, Robert, Willey, Sarah, Wiggenhorn, Christopher, Friedman, Paul A. , Friedman, Paul A , Knight, Bradley P , Boersma, Lucas , Crozier, Ian

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 29, 2021 | Volume: 32 | Issue: 9 | Pages: 2371-2378

10.1111/jce.15190 | PMID 34322918 Get It

AbstractBackgroundTransvenous implantable cardioverter defibrillators (TV ICD) provide life‐saving therapy for millions of patients worldwide. However, they are susceptible to several potential short‐ and long‐ term complications including cardiac perforation and pneumothorax, lead dislodgement, venous obstruction, and infection. The extravascular ICD system's novel design and substernal implant approach avoids the risks associated with TV ICDs while still providing pacing features and similar generator size to TV ICDs.Study DesignThe EV ICD pivotal study is a prospective, multicenter, single‐arm, nonrandomized, premarket clinical study designed to examine the safety and acute efficacy of the system. This study will enroll up to 400 patients with a Class I or IIa indication for implantation of an ICD. Implanted subjects will be followed up to approximately 3.5 years, depending on when the patient is enrolled.ObjectiveThe clinical trial is designed to demonstrate safety and effectiveness of the EV ICD system in human use. The safety endpoint is freedom from major complications, while the efficacy endpoint is defibrillation success. Both endpoints will be assessed against prespecified criteria. Additionally, this study will evaluate antitachycardia pacing performance, electrical performance, extracardiac pacing sensation, asystole pacing, appropriate and inappropriate shocks, as well as a summary of adverse events.ConclusionThe EV ICD pivotal study is designed to provide clear evidence addressing the safety and efficacy performance of the EV ICD System.
Game Utilization and Performance Following RTP From ACL Reconstruction Does not Influence a Subsequent Second ACL Injury in National Football League Players
Khalil, Lafi S. , Lindsay-Rivera, Kevin, Shah, Sabin, Tandron, Marissa , Ferris, Albert, Okoroha, Kelechi R. , Abbas, Muhammad J.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | July 29, 2021 | Volume: 3 | Issue: 5 | Pages: No page available

10.1016/j.asmr.2021.07.002 | PMID 34746844 Get It

Purpose The purpose of this study is to evaluate differences in game utilization or performance following primary anterior cruciate ligament (ACL) reconstruction between National Football League (NFL) players with and without a second ACL injury. Methods NFL players who underwent ACL reconstruction between 2013 and 2017 were identified. Players were classified as having one injury (“tear”) or having later sustained a subsequent second (reinjury or contralateral) ACL injury (“retear”). Players were excluded if they tore their ACL prior to the NFL, did not return to play (RTP), did not play the season before injury, or had concomitant injuries. Demographic characteristics, game utilization statistics, and season approximate value (SAV) performance metrics were recorded. Statistical analysis compared data after RTP from primary ACL reconstruction (seasons +1, +2, and +3) relative to the season before injury (season −1) between cohorts using mean differences and relative percentages. Results Analysis included a total of 45 players, 32 in the “tear” group and 13 in the “retear” group. Demographics, level of play, and time to RTP after primary ACL reconstruction did not differ between the groups ( P > .05). Tear and retear groups demonstrated similar utilization and performance metrics the season prior to injury (−1) and the 3 seasons following RTP (season of injury is “0”). Both groups had a similar decrease (relative percentage) in games played and started, snap counts, and SAV during the 3 seasons following RTP compared to baseline ( P > .05). The draft pick position was correlated with the relative percentage of games started the first season after RTP ( r = .6, P = .02). Conclusions Game utilization and performance metrics following ACL reconstruction were not associated with a subsequent second ACL injury. Players with a higher draft pick position were more likely to return to the starting lineup following primary ACL reconstruction. Ultimately, player game utilization and performance following primary ACL reconstruction is not predictive of a subsequent second ACL injury. Level of Evidence Level III, retrospective case‐control study
Eosinophil‐Derived Neurotoxin Predicts Response to Proton‐Pump Inhibitor Treatment in Pediatric Eosinophilic Esophagitis
Irastorza, Laura E., Hopson, Puanani, Nabar, Shruti, Deb, Chirajyoti, Smadi, Yamen, Irastorza, Laura E., Hopson, Puanani, Nabar, Shruti, Deb, Chirajyoti, Smadi, Yamen

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | July 29, 2021 | Volume: 74 | Issue: 2 | Pages: 267-271

10.1097/mpg.0000000000003257 | PMID 34321427 Get It

ABSTRACTObjectives:There are no tests or patient factors to help predict the best treatment approach for a patient with eosinophilic esophagitis (EoE). The prevalence of proton‐pump inhibitor (PPI) responsive EoE in children ranges from 30% to 71% with multiple studies showing similar characteristics in responders and nonresponders. Eosinophil‐derived neurotoxin (EDN), an eosinophilic granule protein, measured in esophageal brushing has been shown to be a viable measure of disease activity in EoE. Our aim is to determine if EDN can help predict response to PPI in pediatric patients with EoE.Methods:We conducted a prospective cross‐sectional study to compare EDN between PPI‐responsive and PPI‐nonresponsive EoE subjects from 2018 through 2020. Enrolled patients with active EoE were treated with high‐dose PPI and underwent repeat endoscopy to determine PPI‐responsiveness. EDN was measured at baseline endoscopy, before any treatment, and at follow up endoscopy, after PPI therapy. Subjects were divided into PPI‐responsive and nonresponsive groups. EDN, endoscopic reference score (EREFS), and peak eosinophilic count (PEC) were compared.Results:Fifteen out of the 36 enrolled subjects with EoE (age range 2–18 years, 73.3% male) were PPI‐responsive and 21 (age range 2–19 years, 95.2% male) were PPI‐nonresponsive. EDN concentration was significantly higher in the PPI‐nonresponsive group than in the PPI‐responsive group (219.1 ± 229 mcg/mL vs 75.7 ± 60 mcg/mL, respectively, P = 0.036). There was no difference between the two groups in EREFS (P = 0.55) or PEC (P = 0.15).Conclusions:EDN measured in esophageal epithelial samples obtained by brushing during endoscopy may predict PPI‐responsiveness in children and young adults with EoE.
Ergonomics in Spine Surgery
Wagner, Scott C. , Sebastian, Arjun S. , Kolz, Joshua M. , Vaccaro, Alexander R.

Mayo Clinic

Clinical Spine Surgery | July 29, 2021 | Volume: 35 | Issue: 8 | Pages: 333-340

10.1097/bsd.0000000000001238 | PMID 34321393 Get It

As physician burnout and wellness become increasingly recognized as vital themes for the medical community to address, the topic of chronic work-related conditions in surgeons must be further evaluated. While improving ergonomics and occupational health have been long emphasized in the executive and business worlds, particularly in relation to company morale and productivity, information within the surgical community remains relatively scarce. Chronic peripheral nerve compression syndromes, hand osteoarthritis, cervicalgia and back pain, as well as other repetitive musculoskeletal ailments affect many spinal surgeons. The use of ergonomic training programs, an operating microscope or exoscope, powered instruments for pedicle screw placement, pneumatic Kerrison punches and ultrasonic osteotomes, as well as utilizing multiple surgeons or microbreaks for larger cases comprise several methods by which spinal surgeons can potentially improve workspace health. As such, it is worthwhile exploring these areas to potentially improve operating room ergonomics and overall surgeon longevity.